Senseonics Holdings, Inc. to Join Upcoming Conference
GERMANTOWN, Md. — Senseonics Holdings, Inc. (NYSE American: SENS), a prominent medical technology firm focused on long-term implantable continuous glucose monitoring (CGM) systems for diabetes management, has announced its participation in a notable investment event. The H.C. Wainwright 26th Annual Global Investment Conference is set to occur in New York, showcasing groundbreaking advancements in the industry.
Management Presentation Schedule
The management team at Senseonics is scheduled to present on Tuesday at 11:30 AM ET. During this time, they will also hold one-on-one meetings. This event presents a valuable opportunity for investors and stakeholders to gain insights into the company’s vision and the groundbreaking technology that is revolutionizing diabetes care.
Leading-Edge Technology
At the forefront of medical technology, Senseonics offers unique glucose monitoring solutions. Their flagship product, the Eversense® E3 CGM system, features a compact sensor that is implanted beneath the skin and pairs with a smart transmitter worn externally. This cutting-edge technology enables users to receive real-time glucose data every five minutes through a mobile application on their smartphones, greatly simplifying diabetes management.
The Future of Diabetes Management
Senseonics aims to improve the quality of life for individuals within the global diabetes community. Their long-term implantable glucose management technology not only tracks glucose levels but also provides users with easy access to their health data. This empowers them to take better control of their health and make informed decisions regarding their diabetes management.
Engaging with Stakeholders
For those keen on following Senseonics' developments, a live and recorded webcast of the presentation will be available in the Investor Relations section of the company’s website. This webcast serves as a valuable resource for investors looking to understand the company’s strategies and innovations in the diabetes technology sector.
Contacting Senseonics
For any questions or additional information, the investor relations contact at Senseonics is Jeremy Feffer from LifeSci Advisors. He is available to respond to inquiries regarding the company, its products, and investment opportunities. Interested individuals can reach out via the provided email for further communication.
Frequently Asked Questions
What is the main focus of Senseonics Holdings, Inc.?
Senseonics specializes in creating long-term, implantable continuous glucose monitoring systems tailored for individuals with diabetes.
What is the Eversense® E3 system?
The Eversense® E3 system is an advanced glucose monitoring device featuring an implantable sensor beneath the skin, which connects to a smart transmitter for real-time data access.
When and where will the H.C. Wainwright 26th Annual Global Investment Conference take place?
The conference is scheduled for Tuesday and will feature various presentations and one-on-one meetings in New York City.
How can I access the company’s webcast presentation?
Individuals interested in the presentation can access both the live and recorded webcast of Senseonics' presentation through the Investor Relations section of their official website.
Who can I contact for more information about Senseonics?
For more details, investors can contact Jeremy Feffer at LifeSci Advisors via the provided email address for any investor-related inquiries.